Niagen Bioscience, Inc. (NAGE) — 8-K Filings

8-K Filings (15)

• Niagen Bioscience, Inc. Files 8-K for Material Agreement — Dec 22, 2025 Risk: medium
  On December 18, 2025, Niagen Bioscience, Inc. (formerly ChromaDex Corp.) entered into a material definitive agreement. The filing also includes Regulation FD di
• Niagen Bioscience Files 8-K — Nov 6, 2025 Risk: low
  Niagen Bioscience, Inc. filed an 8-K on November 6, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The company, formerly known as Chrom
• Niagen Bioscience Files 8-K — Oct 6, 2025 Risk: low
  Niagen Bioscience, Inc. filed an 8-K on October 6, 2025, reporting information under Regulation FD Disclosure and Financial Statements and Exhibits. The company
• Niagen Bioscience Files 8-K for Material Agreement — Jul 29, 2025 Risk: medium
  Niagen Bioscience, Inc. filed an 8-K on July 29, 2025, reporting a material definitive agreement entered into on July 25, 2025. The filing also includes financi
• Niagen Bioscience Reports Director/Officer Changes & Shareholder Votes — Jun 27, 2025 Risk: medium
  Niagen Bioscience, Inc. filed an 8-K on June 27, 2025, reporting on events as of June 24, 2025. The filing covers the departure of directors or officers, electi
• Niagen Bioscience Changes Fiscal Year End — Mar 19, 2025 Risk: low
  Niagen Bioscience, Inc. filed an 8-K on March 19, 2025, reporting a change in its fiscal year end to December 31. The company, formerly known as ChromaDex Corp.
• ChromaDex Corp. Names New Directors, Adjusts Executive Pay — Feb 27, 2025 Risk: medium
  ChromaDex Corporation announced on February 25, 2025, changes in its board of directors and executive compensation. Specifically, the company elected two new di
• ChromaDex Changes Auditors to Ernst & Young — Dec 16, 2024 Risk: medium
  ChromaDex Corporation announced on December 13, 2024, a change in its certifying accountant. The company has dismissed PricewaterhouseCoopers LLP as its indepen
• ChromaDex Corp. Files 8-K Report — Dec 4, 2024 Risk: low
  On December 4, 2024, ChromaDex Corp. filed an 8-K report detailing "Other Events." The filing does not provide specific details on the nature of these events, t
• ChromaDex Corp. Files 8-K for Material Definitive Agreement — Nov 21, 2024 Risk: medium
  On November 20, 2024, ChromaDex Corp. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive offices i
• ChromaDex Changes Auditors to BDO USA — Oct 11, 2024 Risk: medium
  On October 8, 2024, ChromaDex Corp. filed an 8-K report to disclose changes in its certifying accountant. The company has dismissed PricewaterhouseCoopers LLP a
• ChromaDex Appoints New CSO, Adds Director — Sep 20, 2024 Risk: low
  ChromaDex Corp. announced on September 19, 2024, the appointment of Dr. Robert H. Eckman as Chief Scientific Officer and the election of Ms. Sarah E. McSweeney
• ChromaDex Corp. Elects New Directors, Appoints CFO — Jul 16, 2024 Risk: medium
  ChromaDex Corp. announced on July 16, 2024, changes in its board of directors and executive compensation. Specifically, the company elected two new directors, D
• ChromaDex Appoints New CSO, Adds Director — Jun 25, 2024 Risk: low
  ChromaDex Corporation announced on June 19, 2024, the appointment of Dr. Robert Griffin as Chief Scientific Officer and the election of Ms. Sarah McSweeney to i
• ChromaDex Corp. Reports on Shareholder Vote — Jun 24, 2024 Risk: low
  ChromaDex Corp. filed an 8-K on June 24, 2024, reporting on a shareholder meeting held on June 20, 2024. The primary purpose of the meeting was for security hol

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX